While executives at Ozempic might be wining and dining doctors, not everyone is enjoying a celebratory Toast…

Analysts at Mizuho worry that consumers will be pulling back on dining out, and Toast will suffer over the long term as a result. 

Ozempic prescriptions in the U.S. reached an all-time high in the last week of February, with over 373,000 prescriptions filled, according to a J.P. Morgan analysis of IQVIA data shared with CNN. That’s an increase of 111%, compared with the same time last year. Of these, more than half were new prescriptions, CNN said. 

Toast derives the lion’s share of its revenue from restaurant sales. In a note out October 1, Mizuho’s Dan Dolev and his team lowered their price target for Toast’s stock and downgraded the company, in large part because of these concerns.